Healthcare Executive Passes Out During Weight Loss Drug Announcement
Gordon Findlay, Healthcare Executive of Novo Nordisk, fainted at the Oval Office on Thursday during an event about weight loss drugs.
Incident Details
The GLP-1 announcement was paused immediately, and the press was asked to leave the room as attention turned to Findlay. President Donald Trump and Dr. Mehmet Oz noticed the situation.
“During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted,” White House Press Secretary Karoline Leavitt said. “The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Event Context
During the announcement, President Trump revealed a new agreement with Eli Lilly and Novo Nordisk to offer some obesity drugs at approximately $150 per month's supply for Americans.
While multiple speakers addressed the audience, Findlay fainted during Eli Lilly CEO David Ricks' speech. Following this, the media was cleared from the room. Dr. Kennedy left to provide medical assistance, according to White House Deputy Press Secretary Kush Desai.
The press conference resumed at 1:29 p.m.
Author's summary: During a White House announcement on affordable weight loss drugs, Novo Nordisk executive Gordon Findlay fainted, causing a brief pause before the event resumed.